Homegrown biosimilars are rapidly expanding their influence in the KRW 100 billion-a-year Avastin market. Biosimilars’ sales have increased to exceed 40% in less than 2 years. Samsung Bioepis' Onbevzi led the growth with sales close to the original drug.

According to the market research firm IQVIA, the market size of bevacizumab anticancer drugs in Q1 this year reached KRW 32.7 billion, up 10.8% year-on-year. Compared to the KRW 21.1 billion in Q1 2022, the market has expanded 54.8% in 2 years.

The original bevacizumab drug is Roche’s Avastin. It is an anti-cancer drug used for metastatic colorectal and metastatic breast cancer, non-small cell lung cancer, advanced or metastatic renal cel